



Hysingla™ ER (hydrocodone bitartrate) – First-time generic

- On March 4, 2021, Alvogen launched an [AB-rated](#) generic version of Purdue Pharma's [Hysingla ER \(hydrocodone\)](#) extended-release tablets.
- Hysingla ER is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
- Hydrocodone bitartrate is available generically as an [extended-release capsule](#). Hydrocodone bitartrate is available generically in combination with acetaminophen as a [tablet](#) and [oral solution](#) and in combination with ibuprofen as a [tablet](#).
- Hydrocodone bitartrate extended-release capsules, hydrocodone bitartrate/acetaminophen and hydrocodone bitartrate/ibuprofen carry a similar indication as Hysingla ER.
- In addition, hydrocodone bitartrate is also available generically in combination with other products for the treatment of cough and cold symptoms.
- Hysingla ER carries a boxed warning for addiction, abuse, and misuse; risk evaluation and mitigation strategy (REMS); life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction; and risks from concomitant use with benzodiazepines or other central nervous system depressants.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.